Upadacitinib Population Pharmacokinetics and Exposure-Response Relationships in Ulcerative Colitis Patients

BACKGROUND AND OBJECTIVE: Upadacitinib, an oral selective and reversible Janus kinase (JAK) inhibitor, showed favorable efficacy and safety in patients with moderate-to-severe ulcerative colitis (UC). The objective was to characterize upadacitinib pharmacokinetics in UC patients across Phase 2b and...

Descripción completa

Detalles Bibliográficos
Autores principales: Ponce-Bobadilla, Ana Victoria, Stodtmann, Sven, Eckert, Doerthe, Zhou, Wen, Liu, Wei, Mohamed, Mohamed-Eslam F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9898395/
https://www.ncbi.nlm.nih.gov/pubmed/36571701
http://dx.doi.org/10.1007/s40262-022-01191-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9898395/
https://www.ncbi.nlm.nih.gov/pubmed/36571701
http://dx.doi.org/10.1007/s40262-022-01191-6

Ejemplares similares